Home › Funds › Octagon Capital Advisors LP › PALI
Octagon Capital Advisors LP position in PALI
PALISADE BIO INC · Health Care
Octagon Capital Advisors LP reported holding 10,276,317 shares of PALI (PALISADE BIO INC) in its Q3 2026 13F filing — a position valued at US$13.9M, representing 1.85% of its reported portfolio and ranking #15 among its reported holdings. Octagon Capital Advisors LP has disclosed PALI holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's PALI position evolved
Octagon Capital Advisors LP first disclosed a stake in PALI in Q4 2025 at 9,567,898 shares (US$22.5M). Across 4 filings, Octagon Capital Advisors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 10,276,317 shares valued at US$13.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 9.57M | $22.48M | New |
| Q1 2026 | 10.28M | $17.98M | Add |
| Q2 2026 | 10.28M | $21.48M | Hold |
| Q3 2026 | 10.28M | $13.87M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PALI and 13F data
PALI (PALISADE BIO INC) is a Health Care company. 75 other funds we track also report a position in PALI — the largest reported positions include Soleus Capital Management, L.P. (US$20.2M), B Group, Inc. (US$15.4M), Boxer Capital Management, LLC (US$6.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PALI
- Soleus Capital Management, L.P. 15.00M sh · $20.24M · Q3 2026
- B Group, Inc. 11.41M sh · $15.41M · Q3 2026
- Boxer Capital Management, LLC 4.80M sh · $6.48M · Q3 2026
- Squadron Capital Management LLC 3.00M sh · $4.05M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.34M sh · $3.15M · Q3 2026
- Propel Bio Management, LLC 2.22M sh · $3.00M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 2.18M sh · $2.95M · Q3 2026
- Creek Drive Management Group LLC 680.00K sh · $918.00K · Q3 2026
- ACT CAPITAL MANAGEMENT, LLC 307.50K sh · $642.67K · Q2 2026
- ACT Capital Partners, L.P. 307.50K sh · $415.12K · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held PALI?
Octagon Capital Advisors LP has disclosed PALI holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Octagon Capital Advisors LP's current position in PALI?
As of Q3 2026, Octagon Capital Advisors LP holds 10.28M shares of PALI (PALISADE BIO INC), valued at $13.87M, representing 1.85% of its reported portfolio and ranking #15.
Has Octagon Capital Advisors LP been buying or selling PALI?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP held unchanged its position in PALI.
Which other funds hold PALI?
Other major institutional holders of PALI include Soleus Capital Management, L.P., B Group, Inc., Boxer Capital Management, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.